Li Jing, Wang Bo-Long, Feng Rui-Bing, Li Guo-Dong
School of Chemical and Biological Engineering, Yichun University, Yichun, Jiangxi 336000, China. wblong77 @126.com.
Zhongguo Dang Dai Er Ke Za Zhi. 2016 Jun;18(6):527-33. doi: 10.7499/j.issn.1008-8830.2016.06.012.
To systematically investigate the efficacy and safety of glucocorticoids (GCs) combined with intravenous injection of immunoglobulin (IVIG) in the initial treatment of Kawasaki disease (KD).
EDLINE Database, PubMed Database, CNKI, Wanfang Data, and VIP Database were searched to collect prospective or retrospective controlled studies on the combination of GCs and IVIG as the initial treatment of KD, which were published up to March 2016. Two investigators independently screened the literature, extracted data, and assessed the quality of the articles included. Then, a Meta analysis was performed using RevMan 5.2 software.
A total of 11 articles in English were included, with 7 prospective studies and 4 retrospective studies. The results of the Meta analysis showed that compared with the group using IVIG alone, the combination group had a significantly lower incidence rate of coronary artery lesion (CAL) (OR=0.44, 95%CI 0.23-0.86, P=0.02) and a significantly shorter duration of fever (MD=-1.66, 95%CI -2.32 to -1.01, P<0.00001). The combination group had a significantly lower rate of no response to initial treatment than the IVIG alone group (OR=0.37, 95%CI 0.27-0.51, P<0.00001). The recurrence rate of KD and the incidence rate of adverse events showed no significant differences between the two groups.
GCs combined with IVIG as the initial treatment for KD can reduce the incidence rate of CAL and the rate of no response to initial treatment and shorten the duration of fever, and does not increase the recurrence rate of KD and the incidence rate of adverse events.
系统研究糖皮质激素(GCs)联合静脉注射免疫球蛋白(IVIG)用于川崎病(KD)初始治疗的疗效和安全性。
检索EDLINE数据库、PubMed数据库、中国知网、万方数据和维普数据库,收集截至2016年3月发表的关于GCs联合IVIG作为KD初始治疗的前瞻性或回顾性对照研究。两名研究者独立筛选文献、提取数据并评估纳入文章的质量。然后,使用RevMan 5.2软件进行Meta分析。
共纳入11篇英文文章,其中前瞻性研究7篇,回顾性研究4篇。Meta分析结果显示,与单独使用IVIG组相比,联合组冠状动脉病变(CAL)发生率显著降低(OR=0.44,95%CI 0.23 - 0.86,P=0.02),发热持续时间显著缩短(MD=-1.66,95%CI -2.32至-1.01,P<0.00001)。联合组初始治疗无反应率显著低于单独使用IVIG组(OR=0.37,95%CI 0.27 - 0.51,P<0.00001)。两组KD复发率和不良事件发生率差异无统计学意义。
GCs联合IVIG作为KD的初始治疗可降低CAL发生率和初始治疗无反应率,缩短发热持续时间,且不增加KD复发率和不良事件发生率。